Key result
The HRC Ser96Ala genetic variant independently predicted atrial fibrillation recurrence after radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation (HR 2.66).
Why the study?
Atrial fibrillation recurrence after radiofrequency catheter ablation remains a serious issue, and the role of the sarcoplasmic reticulum Ca2+ leak-causing HRC Ser96Ala polymorphism in recurrence was unknown.
Does the HRC Ser96Ala genetic variant predict atrial fibrillation recurrence after radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation?
Cohort (n=579)
No
Does the HRC Ser96Ala genetic variant predict atrial fibrillation recurrence after radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation?
Effect estimate: HR 2.66 (95% CI 1.35-5.00)
p-value: p=0.007
The HRC Ser96Ala genetic variant serves as a significant independent predictor of atrial fibrillation recurrence following radiofrequency catheter ablation in patients with paroxysmal AF.
HRC Ser96Ala should not yet guide post-ablation management in paroxysmal AF; leaves open need for prospective validation.
BACKGROUND: Atrial fibrillation (AF) recurrence after radiofrequency catheter ablation (RFCA) still remains a serious issue. Ca2+ handling has a considerable effect on AF recurrence. The histidine-rich calcium-binding protein (HRC) genetic single nucleotide polymorphism (SNP), rs3745297 (T>G, Ser96Ala), is known to cause a sarcoplasmic reticulum Ca2+ leak. We investigated the association between HRC Ser96Ala and AF recurrence after RFCA in paroxysmal AF (PAF) patients. METHODS AND RESULTS: We enrolled PAF patients who underwent RFCA (N = 334 for screening and N = 245 for replication) and were genotyped for HRC SNP (rs3745297). The patient age was younger and rate of diabetes and hypertension lower in the PAF patients with Ser96Ala than in those without (TT/TG/GG, 179/120/35; 64±10/60±12/59±13 y, P = 0.001; 18.5/ 9.2/8.6%, P = 0.04 and 66.1/50.0/37.1%, P = 0.001, respectively). During a mean 19 month follow-up, 57 (17.1%) patients suffered from AF recurrences. The rate of an Ser96Ala was significantly higher in patients with AF recurrence than in those without in the screening set (allele frequency model: odds ratio [OR], 1.80; P = 0.006). We also confirmed this significant association in the replication set (OR 1.74; P = 0.03) and combination (P = 0.0008). A multivariate analysis revealed that the AF duration, sinus node dysfunction, and HRC Ser96Ala were independent predictors of an AF recurrence (hazard ratio [HR], 1.04, P = 0.037; HR 2.42, P = 0.018; and HR 2.66, P = 0.007, respectively). CONCLUSION: HRC SNP Ser96Ala is important as a new genetic marker of AF recurrence after RFCA.
No takes yet. Share an insight, caveat, or question.
Amioka et al. (2019) conducted a cohort in Paroxysmal atrial fibrillation (n=579). HRC Ser96Ala genetic variant vs. Absence of HRC Ser96Ala genetic variant (wild type) was evaluated on Late atrial fibrillation recurrence (>2 months after ablation) (HR 2.66, 95% CI 1.35-5.00, p=0.007). The HRC Ser96Ala genetic variant independently predicted atrial fibrillation recurrence after radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation (HR 2.66).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: